{"name":"Mucos Pharma GmbH & Co. KG","slug":"mucos-pharma-gmbh-co-kg","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Phlogenzym","genericName":"Phlogenzym","slug":"phlogenzym","indication":"Other","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Wobenzym® plus","genericName":"Wobenzym® plus","slug":"wobenzym-plus","indication":"Inflammatory and degenerative joint conditions","status":"marketed"}]}],"pipeline":[{"name":"Phlogenzym","genericName":"Phlogenzym","slug":"phlogenzym","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Wobenzym® plus","genericName":"Wobenzym® plus","slug":"wobenzym-plus","phase":"marketed","mechanism":"Wobenzym plus is a proteolytic enzyme combination that reduces inflammation and supports immune modulation through enzymatic breakdown of inflammatory mediators and immune complexes.","indications":["Inflammatory and degenerative joint conditions","Post-operative swelling and inflammation","Immune support and inflammation management"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}